BiotechTube

NC-503 (Anti-amyloidotic (AA) Agent)

Phase 2/3Completed
1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Secondary (AA) Amyloidosis

Conditions

Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome, Familial Mediterranean Syndrome, Kidney Diseases, Gastrointestinal Diseases

Trial Timeline

Oct 1, 2001 → Dec 1, 2004

NCT ID
NCT00035334

About NC-503 (Anti-amyloidotic (AA) Agent)

NC-503 (Anti-amyloidotic (AA) Agent) is a phase 2/3 stage product being developed by GSK plc for Secondary (AA) Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00035334. Target conditions include Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome.

What happened to similar drugs?

6 of 20 similar drugs in Secondary (AA) Amyloidosis were approved

Approved (6) Terminated (0) Active (14)
🔄KHK7580Kyowa KirinPhase 3
🔄KHK7580Kyowa KirinPhase 3
✅Cinacalcet HClKyowa KirinApproved
🔄KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
🔄paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
✅Paricalcitol + CalcifediolAbbVieApproved
✅Paricalcitol + Darbepoetin alfaAbbVieApproved

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00035334Phase 2/3Completed

Competing Products

20 competing products in Secondary (AA) Amyloidosis

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
35
FycompaEisaiPre-clinical
26
FycompaEisaiPre-clinical
26
KHK7580 + KRN1493Kyowa KirinPhase 2/3
38
KHK7580Kyowa KirinPhase 1
29
KHK7580Kyowa KirinPhase 3
40
KHK7580Kyowa KirinPhase 3
40
Cinacalcet HClKyowa KirinApproved
43
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
35
dirucotide + PlaceboEli LillyPhase 2/3
38
dirucotideEli LillyPhase 2/3
30
Paricalcitol + CalcitriolAbbViePre-clinical
18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
40
Paricalcitol + CalcifediolAbbVieApproved
43
Paricalcitol + Darbepoetin alfaAbbVieApproved
43
Birabresib Dose 20 mgMerckPhase 1
21
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
47
RanibizumabNovartisApproved
43
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
43